A flexible COVID-19 model to assess mitigation, “reopening”, virus mutation and other changes
View ORCID ProfileSergio Bienstock
doi: https://doi.org/10.1101/2020.07.09.20150029
Sergio Bienstock
1Deutsche Bank, New York, NY, USA
2Salomon Brothers Inc, New York
3AT&T Bell Labs, Murray Hill, NJ
4Harvard-Smithsonian Center for Astrophysics, Cambridge,MA
5Harvard University, Cambridge, MA
PhD (Retired)Data Availability
All data referred to in the manuscript has been published.
Posted July 11, 2020.
A flexible COVID-19 model to assess mitigation, “reopening”, virus mutation and other changes
Sergio Bienstock
medRxiv 2020.07.09.20150029; doi: https://doi.org/10.1101/2020.07.09.20150029
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2300)
- Dermatology (204)
- Emergency Medicine (372)
- Epidemiology (11629)
- Forensic Medicine (10)
- Gastroenterology (684)
- Genetic and Genomic Medicine (3636)
- Geriatric Medicine (342)
- Health Economics (623)
- Health Informatics (2335)
- Health Policy (921)
- Hematology (336)
- HIV/AIDS (761)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3392)
- Nursing (193)
- Nutrition (512)
- Oncology (1782)
- Ophthalmology (527)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6030)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)